SCHEMBL6423944

SCHEMBL6423944

c1ccc2cc(-c3ncon3)ccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
CYP1A2 P05177 4/20 0.51
CYP11B1 P15538 2/20 0.50
CYP11B2 P19099 2/20 0.50
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 3/20 0.49
KDM4E B2RXH2 3/20 0.49
TP53 P04637 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TSHR P16473 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
KLF5 Q13887 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
S1PR1 P21453 1/20 0.43
NR1H4 Q96RI1 3/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28481167 0.76 RAB9A (0.46) SMN1; SMN2CYP1A2ALDH1A1HSD17B10KDM4E
SCHEMBL30207 0.76 PPARA (0.46) SMN1; SMN2NR1H4NPC1RAB9AKMO
SCHEMBL4527515 0.74 SMN1; SMN2 (0.53) SMN1; SMN2CYP1A2CYP11B1CYP11B2ALDH1A1
SCHEMBL23633460 0.73 ESR1 (0.58) SMN1; SMN2CYP1A2CYP11B1CYP11B2ALDH1A1
SCHEMBL10051440 0.73 GSTP1 (0.52) SMN1; SMN2CYP1A2CYP11B1CYP11B2ALDH1A1
SCHEMBL2463860 0.73 BRD4 (0.49) ALDH1A1HSD17B10KDM4EMEN1KMT2A
SCHEMBL2462858 0.73 S1PR1 (0.49) CYP11B1CYP11B2NPSR1S1PR1NPC1
SCHEMBL17451057 0.72 KDM4E (0.47) SMN1; SMN2CYP1A2CYP11B1CYP11B2ALDH1A1
SCHEMBL2529766 0.72 TDP1 (0.48) SMN1; SMN2CYP11B1CYP11B2ALDH1A1HSD17B10
SCHEMBL2463901 0.71 GSK3B (0.53) ALDH1A1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930104-B2 Heterocyclic derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040157850-A1 Novel heterocyclic derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-08-12 US disclosed
EP-1382598-A1 NOVEL HETEROCYCLIC DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157850-A1 Novel heterocyclic derivatives APP, BACE1, PSEN1 SMN1; SMN2 66/4885CYP1A2 2805/4885CYP11B1 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.